Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial

MLA

Janaka Karalliedde, et al. “Does Dapagliflozin Influence Arterial Stiffness and Levels of Circulating Anti-Aging Hormone Soluble Klotho in People with Type 2 Diabetes and Kidney Disease? Results of a Randomized Parallel Group Clinical Trial.” Frontiers in Cardiovascular Medicine, vol. 9, Sept. 2022. EBSCOhost, https://doi.org/10.3389/fcvm.2022.992327.

APA

Janaka Karalliedde, Nikos Fountoulakis, Dimitra Stathi, Antonella Corcillo, Maria Flaquer, Angeliki Panagiotou, Giuseppe Maltese, Anastasios Mangelis, Salma Ayis, & Luigi Gnudi. (2022). Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial. Frontiers in Cardiovascular Medicine, 9. https://doi.org/10.3389/fcvm.2022.992327

Chicago

Janaka Karalliedde, Nikos Fountoulakis, Dimitra Stathi, Antonella Corcillo, Maria Flaquer, Angeliki Panagiotou, Giuseppe Maltese, Anastasios Mangelis, Salma Ayis, and Luigi Gnudi. 2022. “Does Dapagliflozin Influence Arterial Stiffness and Levels of Circulating Anti-Aging Hormone Soluble Klotho in People with Type 2 Diabetes and Kidney Disease? Results of a Randomized Parallel Group Clinical Trial.” Frontiers in Cardiovascular Medicine 9 (September). doi:10.3389/fcvm.2022.992327.